The global cystic fibrosis therapeutics market was valued at $4,615.4 million in 2018 and is expected to reach $9,277.3 million by 2026, registering a CAGR of 9.2% from 2019 to 2026. Cystic fibrosis is a progressive, hereditary disease that led to insistent lung infections and limits the patient’s ability to breathe over time. Diagnosis of cystic fibrosis is a multistep process, and includes a newborn screening, a sweat test, a genetic or carrier test, and a clinical evaluation. Though people diagnosed with the disease are of age of 2, some are also diagnosed as adults. A specialist can order a sweat test and recommend additional testing to confirm the diagnosis.
Significant rise in incidence of cystic fibrosis across the globe and increase in awareness about its diagnosis are the major factors driving the market growth. In addition, rise in R&D investments by the key players such as Vertex Pharmaceuticals propels the growth of cystic fibrosis therapeutics market. However, high cost of the cystic fibrosis treatment and introduction of generic drugs hinder the growth of the market.
Moreover, development of the healthcare industry and increase in R&D activities undertaken by key players are expected to boost the market growth during the forecast period. Furthermore, rise in prevalence of cystic fibrosis has generated need for newer and advanced therapeutics for its treatment. Thereby, this has led to increase in number of pipeline drugs in the market, which is expected to provide remunerative opportunities for market expansion during the forecast period.
The global cystic fibrosis therapeutic market is segmented based on drug class, route of administration, top selling drug, and region. On the basis of drug class, the market is divided into pancreatic enzyme supplements, mucolytic, bronchodilators, and CFTR modulators. Depending on route of administration, it is classified into oral and inhaled. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
ü The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
ü It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
ü Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
ü Key players are profiled, and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS
• By Drug Class
o Pancreatic Enzyme Supplements
o Mucolytic
o Bronchodilators
o CFTR Modulators
• By Route of Administration
o Oral
o Inhaled
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o France
o UK
o Italy
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o Rest of Asia-Pacific
• LAMEA
o Brazil
o Saudi Arabia
o South Africa
o Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
• Genentech, Inc.
• Novartis AG
• Gilead Sciences, Inc.
• Vertex Pharmaceuticals Incorporated
• AbbVie Inc.
• GlaxoSmithKline Plc.
• Johnson & Johnson
• Allergan plc.
• Pharmaxis Ltd.
• Mylan N.V.
Chapter 1: Introduction
1.1. Report Description
1.2. Key Benefits For Stakeholders
1.3. Key Market Segments
1.4. Research Methodology
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools & Models
Chapter 2: Executive Summary
2.1. Cxo Perspective
Chapter 3: Market Overview
3.1. Market Definition And Scope
3.2. Porter’S Five Forces Analysis
3.3. Top Player Positioning
3.4. Market Dynamics
3.4.1. Drivers
3.4.1.1. Rise In Incidence Of Cystic Fibrosis (Cf)
3.4.1.2. Advancements In Therapeutics For Treatment Of Cystic Fibrosis
3.4.2. Restraints
3.4.2.1. Low Awareness In Developing Nations
3.4.3. Opportunity
3.4.3.1. Surge In R&D Towards The Development Of Novel Therapeutics
Chapter 4: Cystic Fibrosis Therapeutics Market, By Drug Class
4.1. Overview
4.1.1. Market Size And Forecast
4.2. Pancreatic Enzyme Supplements
4.2.1. Key Market Trends And Opportunities
4.2.2. Market Size And Forecast
4.2.3. Market Analysis, By Country
4.3. Mucolytics
4.3.1. Key Trends And Opportunities
4.3.2. Market Size And Forecast
4.3.3. Market Analysis, By Country
4.4. Bronchodilators
4.4.1. Key Market Trends And Opportunities
4.4.2. Market Size And Forecast
4.4.3. Market Analysis, By Country
4.5. Cftr Modulators
4.5.1. Key Trends And Opportunities
4.5.2. Market Size And Forecast
4.5.3. Market Analysis, By Country
Chapter 5: Cystic Fibrosis Therapeutics Market, By Route Of Administration
5.1. Overview
5.1.1. Market Size And Forecast
5.2. Oral
5.2.1. Market Size And Forecast
5.2.2. Market Analysis, By Country
5.3. Inhale
5.3.1. Market Size And Forecast
5.3.2. Market Analysis, By Country
Chapter 6: Cystic Fibrosis Therapeutics Market, By Region
6.1. Overview
6.1.1. Market Size And Forecast
6.2. North America
6.2.1. Key Trends And Opportunities
6.2.2. North America Market Size And Forecast, By Country
6.2.2.1. U.S. Market Size And Forecast, By Drug Class
6.2.2.2. U.S. Market Size And Forecast, By Route Of Administration
6.2.2.3. Canada Market Size And Forecast, By Drug Class
6.2.2.4. Canada Market Size And Forecast, By Route Of Administration
6.2.2.5. Mexico Market Size And Forecast, By Drug Class
6.2.2.6. Mexico Market Size And Forecast, By Route Of Administration
6.2.3. North America Market Size And Forecast, By Drug Class
6.2.4. North America Market Size And Forecast, By Route Of Administration
6.3. Europe
6.3.1. Key Trends And Opportunities
6.3.2. Europe Market Size And Forecast, By Country
6.3.2.1. Germany Market Size And Forecast, By Drug Class
6.3.2.2. Germany Market Size And Forecast, By Route Of Administration
6.3.2.3. Uk Market Size And Forecast, By Drug Class
6.3.2.4. Uk Market Size And Forecast, By Route Of Administration
6.3.2.5. France Market Size And Forecast, By Drug Class
6.3.2.6. France Market Size And Forecast, By Route Of Administration
6.3.2.7. Rest Of Europe Market Size And Forecast, By Drug Class
6.3.2.8. Rest Of Europe Market Size And Forecast, By Route Of Administration
6.3.3. Europe Market Size And Forecast, By Drug Class
6.4. Asia-Pacific
6.4.1. Key Trends And Opportunities
6.4.2. Asia-Pacific Market Size And Forecast, By Country
6.4.2.1. Japan Market Size And Forecast, By Drug Class
6.4.2.2. Japan Market Size And Forecast, By Route Of Administration
6.4.2.3. China Market Size And Forecast, By Drug Class
6.4.2.4. China Market Size And Forecast, By Route Of Administration
6.4.2.5. India Market Size And Forecast, By Drug Class
6.4.2.6. India Market Size And Forecast, By Route Of Administration
6.4.2.7. Australia Market Size And Forecast, By Drug Class
6.4.2.8. Australia Market Size And Forecast, By Route Of Administration
6.4.2.9. Rest Of Asia-Pacific Market Size And Forecast, By Drug Class
6.4.2.10. Rest Of Asia-Pacific Market Size And Forecast, By Route Of Administration
6.4.3. Asia-Pacific Market Size And Forecast, By Drug Class
6.4.4. Asia-Pacific Market Size And Forecast, By Route Of Administration
6.5. Lamea
6.5.1. Key Market Trends And Opportunities
6.5.2. Lamea Market Size And Forecast, By Country
6.5.2.1. Brazil Market Size And Forecast, By Drug Class
6.5.2.2. Brazil Market Size And Forecast, By Route Of Administration
6.5.2.3. South Africa Market Size And Forecast, By Drug Class
6.5.2.4. South Africa Market Size And Forecast, By Route Of Administration
6.5.2.5. Saudi Arabia Market Size And Forecast, By Drug Class
6.5.2.6. Saudi Arabia Market Size And Forecast, By Route Of Administration
6.5.2.7. Rest Of Lamea Market Size And Forecast, By Drug Class
6.5.2.8. Rest Of Lamea Market Size And Forecast, By Route Of Administration
6.5.3. Lamea Market Size And Forecast, By Drug Class
6.5.4. Lamea Market Size And Forecast, By Route Of Administration
Chapter 7: Company Profiles
7.1. F. Hoffmann-La Roche Ag
7.1.1. Company Overview
7.1.2. Company Snapshot
7.1.3. Operating Business Segments
7.1.4. Product Portfolio
7.1.5. Business Performance
7.2. Novartis Ag
7.2.1. Company Overview
7.2.2. Company Snapshot
7.2.3. Operating Business Segments
7.2.4. Product Portfolio
7.2.5. Business Performance
7.3. Gilead Sciences, Inc.
7.3.1. Company Overview
7.3.2. Company Snapshot
7.3.3. Operating Business Segments
7.3.4. Product Portfolio
7.3.5. Business Performance
7.4. Vertex Pharmaceuticals Incorporated
7.4.1. Company Overview
7.4.2. Company Snapshot
7.4.3. Operating Business Segments
7.4.4. Product Portfolio
7.4.5. Business Performance
7.4.6. Key Strategic Moves And Developments
7.5. Abbvie Inc.
7.5.1. Company Overview
7.5.2. Company Snapshot
7.5.3. Operating Business Segments
7.5.4. Product Portfolio
7.5.5. Business Performance
7.5.6. Key Strategic Moves And Developments
7.6. Glaxosmithkline Plc.
7.6.1. Company Overview
7.6.2. Company Snapshot
7.6.3. Operating Business Segments
7.6.4. Product Portfolio
7.6.5. Business Performance
7.7. Teva Pharmaceutical Industries Ltd.
7.7.1. Company Overview
7.7.2. Company Snapshot
7.7.3. Operating Business Segments
7.7.4. Product Portfolio
7.7.5. Business Performance
7.8. Allergan Plc
7.8.1. Company Overview
7.8.2. Company Snapshot
7.8.3. Operating Business Segments
7.8.4. Product Portfolio
7.8.5. Business Performance
7.9. Pharmaxis Ltd
7.9.1. Company Overview
7.9.2. Company Snapshot
7.9.3. Operating Business Segments
7.9.4. Product Portfolio
7.10. Mylan N.V
7.10.1. Company Overview
7.10.2. Company Snapshot
7.10.3. Operating Business Segments
7.10.4. Product Portfolio
7.10.5. Business Performance
Trends Market Research © Copyright 2020. All Rights Reserved.
